Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:25:46 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



Q:NBIX - NEUROCRINE BIOSCIENCES INC - http://WWW.NEUROCRINE.COM
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NBIX - Q0.1114.32·149.800.1135.99-1.77-1.3717.696,93813,450137.47  138.63  135.17148.3699  89.04Apr 26Apr 2415 min RT 2¢

Recent Trades - Last 10 of 13450
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-24 08:30U:NBIXNews ReleaseNeurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
2024-04-23 07:00U:NBIXNews ReleaseNeurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
2024-04-16 16:01U:NBIXNews ReleaseSentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
2024-04-10 16:01U:NBIXNews ReleaseNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
2024-04-03 08:30U:NBIXNews ReleaseNeurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
2024-03-28 08:30U:NBIXNews ReleaseNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
2024-03-11 16:01U:NBIXNews ReleaseNeurocrine Biosciences to Participate at Virtual Investor Conferences in March
2024-02-27 16:01U:NBIXNews ReleaseNeurocrine Biosciences to Participate at Investor Conferences in March
2024-02-07 07:00U:NBIXNews ReleaseNeurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
2024-01-17 16:16U:NBIXNews ReleaseNeurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results
2024-01-02 16:01U:NBIXNews ReleaseNeurocrine Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-05 16:01U:NBIXNews ReleaseNeurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia
2023-12-01 07:00U:NBIXNews ReleaseNeurocrine Biosciences to Host Analyst Day on December 5, 2023
2023-11-13 07:00U:NBIXNews ReleaseNeurocrine Biosciences Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation
2023-11-09 16:01U:NBIXNews ReleaseNeurocrine Biosciences Provides Development Pipeline Update
2023-11-08 16:05U:NBIXNews ReleaseNeurocrine Biosciences Launches Interactive Digital Tool for use by Healthcare Providers to Help Expand Education on Identifying and Diagnosing Tardive Dyskinesia
2023-11-08 16:01U:NBIXNews ReleaseNeurocrine Biosciences to Present at the Jefferies London Healthcare Conference
2023-11-02 08:30U:NBIXNews ReleaseNeurocrine Biosciences ‚ ® Presents INGREZZA ‚ ® (valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 50 at Huntington Study Group 2023
2023-10-31 07:00U:NBIXNews ReleaseNeurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
2023-10-10 16:01U:NBIXNews ReleaseNeurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2023 Financial Results